Ohio Adm.Code 4729:1 | Ohio Administrative Code 4729:1 — State Board of Pharmacy | Pharmacists

Chapter 4729:1-1 Definitions

Ohio Adm.Code 4729:1-1-01 Definitions - pharmacists.

As used in this division:

(A) "Abandoned application" means an application for a licensure pursuant to this division where the applicant fails to complete all application requirements within thirty days after being notified by the board. An applicant forfeits all fees associated with an abandoned application. The board shall not be required to act on any abandoned application and the application may be destroyed by board staff. If the application is abandoned, the applicant shall be required to reapply for licensure, submit the required fee and comply with the licensure requirements in effect at the time of reapplication.

(B) "Addicted to or abusing alcohol or drugs" means the chronic and habitual use of alcohol or the use of a drug of abuse as defined in section 3719.011 of the Revised Code by an individual to the extent that the individual no longer can control the individual's use of alcohol or drugs, the individual is physically or psychologically dependent on alcohol or drugs, or the individual's use or abuse of alcohol or drugs endangers the health, safety, or welfare of the individual or others.

(C) "Board of pharmacy" or "board" means the state board of pharmacy established under Chapter 4729. of the Revised Code.

(D) "Business day" means any day other than Saturday, Sunday or a holiday recognized by the state of Ohio on which the offices of the board of pharmacy are not open for business.

(E) "Compounding" has the same meaning as defined in section 4729.01 of the Revised Code and agency 4729 of the Administrative Code.

(F) "Controlled substance" has the same meaning as in section 3719.01 of the Revised Code.

(G) "Disciplinary action," unless otherwise stated in this division, means any of the following by the drug enforcement administration or licensing agency of any state or jurisdiction, regardless of whether the action occurred by formal proceeding, consent, settlement, or other agreement:

(1) An action to revoke, suspend, restrict, limit, or refuse to grant or renew a license, registration, or certification;

(2) A summary or emergency suspension of a license, registration or certification, of any length, and any subsequent revision to the action;

(3) An administrative fine or money penalty, taken as a result of a formal proceeding, to include any fine or money penalty connected to the delivery of health care services or taken in conjunction with other adverse licensure, registration or certification actions, such as revocation, suspension, censure, reprimand, or probation;

(4) An action to reprimand or place the license, registration, or certification holder on probation;

(5) The issuance of a corrective action plan only if such issuance is in conjunction with other adverse licensure, registration or certification actions, such as revocation, suspension, reprimand, probation, or surrender;

(6) The withdrawal of a renewal application for licensure, registration or certification while under investigation;

(7) The non-renewal of a license, registration or certification while under investigation or to avoid an investigation;

(8) The surrender or other relinquishment of a license, registration or certification in lieu of a formal sanction against a person's license, registration, or certificate, whether permanent or temporary;

(9) In lieu of an adverse licensure, registration or certification action, a licensing agency issues a consent order in which a person agrees not to re-apply for a license, registration, or certification in the future;

(10) An enforceable agreement not to practice or to be placed into inactive or other equivalent status while under investigation or in exchange for not conducting an investigation.

(H) "Dispense" means the final association of a drug with a patient pursuant to a prescription, drug order, or other lawful order of a prescriber and the professional judgment of and the responsibility for interpreting, preparing, compounding, labeling, and packaging a specific drug.

(I) "Interpret prescriptions," as used in section 4729.01 of the Revised Code, means the professional judgment of a pharmacist when reviewing a valid prescription order of a prescriber for a patient in accordance with the applicable requirements set forth in agency 4729 of the Administrative Code.

(J) "Personal supervision" or "direct supervision" means a pharmacist shall be physically present in the pharmacy, or in the area where the practice of pharmacy is occurring, to provide personal review and approval of all professional activities.

(K) "Pharmacist" means an individual who holds a valid pharmacist license in accordance with Chapter 4729. of the Revised Code.

(L) "Place on probation" means to take action against a license, for a period of time determined by the board, which imposes conditions or other requirements, or suspends or otherwise restricts some or all of the activities in which the licensee may engage.

(M)

(1) "Positive identification" means a method of identifying a person that does not rely solely on the use of a private personal identifier such as a password, but must use a secure means of identification that includes any of the following:

(a) A manual signature on a hard copy record;

(b) A magnetic card reader;

(d) A biometric method;

(e) A proximity badge reader;

(f) A board approved system of randomly generated personal questions;

(g) A printout of every transaction that is verified and manually signed within a reasonable period of time by the individual who performed the action requiring positive identification. The printout must be maintained for three years and made readily retrievable; or

(h) Other effective methods for identifying individuals that have been approved by the board.

(2) A method relying on a magnetic card reader, a bar code reader, a proximity badge reader, or randomly generated questions for identification must also include a private personal identifier, such as a password, for entry into a secure mechanical or electronic system.

(N) "Practice of pharmacy" has the same meaning as in division (B) of section 4729.01 of the Revised Code.

(O) "Readily retrievable" means that records maintained in accordance with this division shall be kept in such a manner that, upon request, they can be produced for review no later than three business days to an agent, officer or inspector of the board.

(P) "Responsible person" has the same meaning as defined in rule 4729:5-2-01 of the Administrative Code.

(Q) "Refuse to grant or renew" means to deny original or continued licensure for a period of at least twenty-four months. After twenty-four months, or such period of time as the individual board order may require, a person licensed by the board or a person seeking to attain such status by licensure, and whose license the state board of pharmacy has refused to grant or renew, may make application to the board for issuance of a new license. A person that seeks to attain such status by licensure, whose license the state board of pharmacy has refused to grant or renew, must meet all requirements established by the board in rule and as may be set forth in the person's board order.

(R) "Revoke" means to take action against a license rendering such license void and such license shall not be reissued. "Revoke" is an action that is permanent against the licensee.

(S) "State" means a state of the United States, the District of Columbia, the Commonwealth of Puerto Rico or a territory or insular possession subject to the jurisdiction of the United States.

(T) "Suspend" means to take action against a license rendering such license without force and effect for a period of time as determined by the state board of pharmacy. The board may require that an individual whose license or registration has been suspended may not be employed by or work in a facility licensed by the state board of pharmacy to possess or distribute dangerous drugs during such period of suspension.

(U) "Summary suspension" means to take immediate action against a license without a prior hearing rendering such license without force and effect for a period of time as indicated in section 3719.121 of the Revised Code. The board may suspend a license issued pursuant to Chapter 4729. of the Revised Code by utilizing a telephone conference call to review the allegations and take a vote.

(V) "Veteran" means anyone who is serving or has served under honorable conditions in any component of the armed forces, including the national guard and reserve.

Last updated April 25, 2022 at 8:26 AM

History

Effective: April 25, 2022
Promulgated Under: 119.03

Chapter 4729:1-2 Licensing of Pharmacists

Ohio Adm.Code 4729:1-2-01 Criteria for licensure by examination.

(A) Pursuant to sections 4729.07 and 4729.13 of the Revised Code, pharmacist licensure by examination shall consist of:

(1) The "North American Pharmacist Licensure Examination" (NAPLEX) administered by the national association of boards of pharmacy (NABP); and

(2) A jurisprudence examination which shall be one of the following as determined by the board:

(a) The "Multistate Pharmacy Jurisprudence Examination" (MPJE) administered by the national association of boards of pharmacy (NABP); or

(b) A jurisprudence examination administered by NABP and approved by the board.

(B) Unless otherwise approved by the board, the minimum passing score on each examination shall be determined by NABP.

(1) Any candidate who fails to receive a passing score on the NAPLEX examination shall make application and remit the fee established by the state board of pharmacy for re-examination.

(2) Any candidate who fails to receive a passing score on the jurisprudence examination shall make application and remit the fee established by the state board of pharmacy for re-examination.

(C) A candidate may use the NABP process to transfer the candidate's NAPLEX score to Ohio only after the candidate has met all of the requirements set by the board for examination and licensure in Ohio.

(D) Pursuant to section 4729.08 of the Revised Code, graduates of unapproved schools or colleges of pharmacy located outside the United States who are using an approved examination to establish equivalency of their education shall:

(1) Obtain a passing score, as determined by NABP, on the "Foreign Pharmacy Graduate Equivalency Examination (FPGEE)"; and

(2) Show oral proficiency in English by successful completion of the "Test of English as a Foreign Language, Internet-based test" (TOEFL iBT) pursuant to rule 4729:1-2-04 of the Administrative Code.

(E) Any examination candidate who fails to take both of the required examinations pursuant to paragraph (A) of this rule within twelve months from the date the board receives the application materials shall submit a new application for the required examination or examinations and remit the fee established by the board, as the original application shall be deemed abandoned.

(F) The record of the passing score for an examination candidate who takes both of the required examinations pursuant to paragraph (A) of this rule, but successfully only completes one examination will:

(1) Be maintained up to three years if no more than twelve months has elapsed between attempts to successfully complete the remaining examination.

(2) Not be maintained if more than twelve months has elapsed between attempts to successfully complete the remaining examination. It will then be necessary for the examination candidate to repeat both examinations for Ohio licensure.

(G) Any candidate who has requested to transfer their NAPLEX score to Ohio must successfully complete the jurisprudence examination within twelve months from the date the candidate completed the NAPLEX examination or the score transfer will be denied.

(H) Pursuant to section 4729.071 of the Revised Code, a candidate must submit electronic or ink fingerprint impressions for a criminal records check prior to receiving approval to take the required examinations. An examination candidate must submit fingerprint impressions no later than sixty days after the date the board receives the application materials. After sixty days, a candidate must submit a new application, the required fee, and fingerprint impressions, as the original application shall be deemed abandoned.

(I) Candidates shall be limited to a total of five attempts to pass the NAPLEX and the jurisprudence examination. The board may grant one additional attempt to pass the NAPLEX and the jurisprudence examination in the event of extraordinary circumstances. A candidate that exceeds the limits set forth in this paragraph is no longer eligible to obtain licensure as a pharmacist by examination pursuant to this rule.

(J) Pursuant to section 4729.16 of the Revised Code, a limited or restricted license may be issued to an applicant upon the determination of the board.

Last updated January 15, 2025 at 7:58 AM

History

Effective: January 15, 2025
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-2-04

Successful completion of the "Test of English as a Foreign Language, Internet-based test" (TOEFL iBT) shall be the following minimum scores or higher:

(A) Writing: twenty-four;

(B) Speaking: twenty-six;

(D) Reading: twenty-two.

Last updated May 19, 2026 at 3:55 PM

History

Effective: September 15, 2017
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-2-02 Criteria for licensure by reciprocity.

(A) An applicant seeking licensure as a pharmacist by reciprocity shall comply with all the following:

(1) Be at least eighteen years of age.

(2) Obtain a degree in pharmacy from a school of pharmacy approved by the state board of pharmacy.

(3) Have met the applicable practical experience requirements by either:

(a) Successfully graduating after December 31, 2006 with a doctor of pharmacy degree (Pharm.D.) from a school of pharmacy approved by the state board of pharmacy; or

(b) Obtaining a total of at least one thousand seven hundred and forty hours of documented supervised practical experience in Ohio or any other state or jurisdiction in which the credentials are at least the equivalent of those required by this state at the time the experience was obtained. If the reciprocating state or jurisdiction requires less than the required hours, the board may grant internship credit for practice as a pharmacist.

(4) Hold an active license or registration to practice pharmacy, which is in good standing, in a state or jurisdiction in which the credentials are at least the equivalent of those required by this state. Certification of these credentials shall be conducted by the national association of boards of pharmacy (NABP).

(B) An applicant who has met the requirements of the state or jurisdiction with which the applicant holds a certificate of good standing pursuant to a "Foreign Pharmacy Graduate Examination Commission (FPGEC)" certificate shall be required to establish proficiency in spoken English by providing evidence of the successful completion of the "Test of English as a Foreign Language, Internet-based test" (TOEFL iBT) pursuant to rule 4729:1-2-04 of the Administrative Code.

(C) Except as provided in rule 4729:1-2-09 of the Administrative Code, candidates who qualify for licensure by reciprocity shall successfully complete a course developed by the board or approved by the board, that includes a scored evaluation component, on Ohio law and rules governing the practice of pharmacy.

(1) Candidates who do not successfully complete this course within six months following the submission of a completed application shall file a new application and required fee for licensure by reciprocity, as the original application shall be deemed abandoned.

(2) The board may require an applicant to complete the jurisprudence examination as defined in rule 4729:1-2-01 of the Administrative Code in lieu of completing the course if the applicant has never obtained a passing score on a jurisprudence examination for any state or jurisdiction.

(3) Paragraph (C)(2) of this rule does not apply to applicant who either:

(a) Received initial licensure prior to January 1, 2018; or

(b) Successfully passed a board approved state jurisprudence examination.

(D) Pursuant to section 4729.071 of the Revised Code, a candidate must submit electronic or ink fingerprint impressions for a criminal records check prior to receiving an initial license to practice as a pharmacist. A reciprocity candidate must submit fingerprint impressions no later than six months after the date the board receives the application materials. After six months, a candidate must submit a new application, the required fee, and fingerprint impressions.

(E) Pursuant to division (B)(2) of section 4796.03 of the Revised Code, the board hereby waives the requirements set forth in division (B)(1) of section 4796.03 of the Revised Code.

(F) Pursuant to division (F)(3) of section 4796.03 of the Revised Code, the required fee for reciprocity shall be three hundred thirty-seven dollars and fifty cents and any transaction fee as required by section 125.18 of the Revised Code.

(G) Pursuant to section 4729.16 of the Revised Code, a limited or restricted license may be issued to an applicant upon the determination of the board.

Last updated January 15, 2025 at 7:58 AM

History

Effective: January 15, 2025
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-2-09

(A) As used in this rule:

(1) "Military duty" has the same meaning as in section 4743.041 of the Revised Code.

(2) "In good standing" means an applicant to which both the following apply:

(a) Has not been denied a license, registration, or certificate by any public agency or licensing agency; and

(b) Does not have a license, registration, or certificate limited, suspended, or revoked by any public agency or licensing agency.

(B) To meet the requirements set forth in section 4743.041 of the Revised Code, the state board of pharmacy shall issue an expedited license to a pharmacist applicant if the individual or the individual's spouse is on military duty in this state and the applicant complies with all the following:

(1) The individual holds a valid license or other authorization to practice as a pharmacist issued by any other state or jurisdiction. Certification of these credentials shall be filed on forms provided by the national association of boards of pharmacy (NABP) or similar forms recognized and approved by the board.

(2) The individual shall be in good standing in the state or jurisdiction of licensure.

(3) The individual presents adequate proof to the board, in accordance with paragraph (G) of this rule, that the individual or the individual's spouse is on military duty in this state.

(4) The individual complies with sections 4776.01 to 4776.04 of the Revised Code. An applicant shall submit fingerprint impressions for a criminal records check in accordance with rule 4729:1-2-05 of the Administrative Code.

(C) The board shall, within twenty-four hours after receiving the report under division (A) of section 4776.04 of the Revised Code, notify an individual applying for an expedited license in accordance with this rule that the board has received the results of a criminal records check.

(D) The board shall issue an expedited pharmacist license under this rule, provided that the applicant meets the requirements of this rule, within fourteen days of having received the results of a criminal records check. The board shall not be required to issue an expedited license if any of the following apply:

(1) The applicant fails to meet the application requirements set forth in this rule or section 4743.041 of the Revised Code.

(2) The applicant is under investigation by the licensing agency of any other state or jurisdiction.

(3) The applicant is in violation of any provision section 4729.16 of the Revised Code or rules adopted thereunder.

(E) Notwithstanding any other provision of the Revised Code or Administrative Code, the board shall waive or refund all fees associated with the issuance of an initial expedited license issued under this rule. Additional fee waivers or refunds shall be granted in accordance with other provisions of the Revised Code, Administrative Code, and board resolution.

(F) All licenses issued pursuant to this rule shall comply with the licensure renewal requirements set forth in Chapter 4729:1-2 of the Administrative Code.

(G) Pursuant to section 5903.04 of the Revised Code:

(1) A pharmacist shall submit proper documentation necessary to determine if the applicant is a service member or veteran, or the spouse or surviving spouse of a service member or veteran. Documentation requirements shall be published on the state board of pharmacy's website: www.pharmacy.ohio.gov.

(2) The board's executive director or the director's designee shall design a process to record, track, and monitor applications that have been received from a service member, veteran, or the spouse or surviving spouse of a service member or veteran.

(3) The board's executive director or the director's designee shall design a process to prioritize and expedite certification or licensing for each applicant who is a service member, veteran, or the spouse or a surviving spouse of a service member or veteran.

Last updated May 15, 2026 at 7:31 AM

History

Effective: May 15, 2026
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-2-03 Examination application for licensure as a pharmacist.

(A) Each person seeking to apply to take the examinations for licensure as a pharmacist shall submit the required application materials and fees to the national association of boards of pharmacy (NABP) and the following to the state board of pharmacy:

(1) A completed application form as provided by the board;

(2) Required fee, including any transaction fee as required by section 125.18 of the Revised Code; and

(3) Either of the following:

(a) A certificate of education completed and certified by an approved school of pharmacy documenting the successful graduation of the applicant with a doctor of pharmacy degree obtained after December 31, 2006; or

(b) The required hours of supervised practical experience pursuant to rule 4729:2-2-05 of the Administrative Code, and either:

(i) A certificate of education completed and certified by an approved school of pharmacy documenting the successful graduation of the applicant; or

(ii) Certification provided by the national association of boards of pharmacy documenting the applicant has established educational equivalency by obtaining a "Foreign Pharmacy Graduate Examination Commission" (FPGEC) certificate and evidence of successful completion of the "Test of English as a Foreign Language, Internet-based test (TOEFL iBT)" pursuant to rule 4729:1-2-04 of the Administrative Code.

(4) Any other information or documentation as determined by the board.

(B) The state board of pharmacy may make an applicant eligible to take the required examinations as soon as the board receives all the items set forth in paragraph (A) of this rule and the results of a criminal records check pursuant to section 4729.071 of the Revised Code.

Last updated March 4, 2024 at 8:39 AM

History

Effective: March 4, 2024
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-2-05 Criminal records check for pharmacists.

(A) Pursuant to section 4729.071 of the Revised Code, an applicant seeking an initial license as a pharmacist by examination or reciprocity must first submit fingerprint impressions to the Ohio bureau of criminal identification and investigation (BCI&I) for a criminal records check.

(B) Pursuant to section 4776.02 of the Revised Code, the criminal records check performed by BCI&I shall consist of both a BCI&I criminal records check and a federal bureau of investigation (FBI) criminal records check. BCI&I shall send the results of the BCI&I and FBI criminal records checks directly to the state board of pharmacy.

(1) Be based on electronic fingerprint impressions that are submitted directly to BCI&I from a WebCheck provider agency or ink impressions. The state board of pharmacy may accept the results of a criminal records check based on ink impressions only in the following circumstances:

(a) Readable electronic fingerprint impressions cannot be obtained or are rejected by either BCI&I or FBI;

(b) The applicant is from out-of-state;

(2) Results will only be considered valid if the fingerprint impressions were obtained within one year of the date the application is received by the board.

Last updated January 3, 2024 at 12:17 PM

History

Effective: March 1, 2018
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-2-06 Pharmacist change of name, address or employment.

(A) A pharmacist, who has a legal change of name, shall notify the board of pharmacy, in a manner determined by the board, within thirty days from the effective date of such change. Such notification of a name change shall be accompanied by one of the following:

(1) A notarized affidavit;

(2) A certified copy of a court record;

(3) A certified copy of a marriage certificate;

(4) A government-issued identification card which reflects the pharmacist's name change; or

(5) Any other documentation as approved by the board.

(B) Requests for a duplicate wall certificate shall be issued in the new name of the pharmacist and shall be accompanied by the required fee. The pharmacist shall promptly destroy the wall certificate that no longer reflects their legal name.

(C) Upon receipt of the required documents and fee pursuant to paragraphs (A) and (B) of this rule, the board will forward the duplicate wall certificate issued in the pharmacist's new name.

(D) A pharmacist who changes their mailing or email address shall notify the board of pharmacy, in a manner determined by the board, of the new address within thirty days after the effective date of such change.

(E) A pharmacist who changes their place of employment shall notify the board of pharmacy, in a manner determined by the board, of the address of the principal place where they practice, including pharmacist placement services, within thirty days after they have commenced such practice.

(F) The board shall only issue a duplicate wall certificate to a pharmacist who has lost, misplaced, or damaged their original wall certificate. A pharmacist seeking a duplicate wall certificate in accordance with this paragraph shall submit a request for a duplicate wall certificate in manner determined by the board and shall pay the required fee of twenty-two dollars and fifty cents.

Last updated March 4, 2024 at 8:40 AM

History

Effective: March 4, 2024
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-2-07 Pharmacist licensure and renewal.

(A) Except as provided in paragraph (B) of this rule, a pharmacist license issued by the state board of pharmacy in accordance with Chapter 4729. of the Revised Code entitles the individual to whom it is issued to practice as a pharmacist until the next renewal date.

(B) An initial pharmacist license issued by the state board of pharmacy on or after the first of May of every odd-numbered year in accordance with Chapter 4729. of the Revised Code entitles the individual to whom it is issued to practice as a pharmacist until the renewal date immediately following the next required renewal date.

(D) An individual who fails to renew their license by the fifteenth day of September of every odd-numbered year shall not engage in the practice of pharmacy until a valid license is issued by the board.

(E) In accordance with section 4729.15 of the Revised Code, the renewal fee shall be two hundred fifty dollars and any transaction fee as required by section 125.18 of the Revised Code.

(F) In accordance with section 4729.15 of the Revised Code, a pharmacist renewing a license that expired less than three years shall pay the renewal fee plus a penalty of thirty-seven dollars and fifty cents.

(G) In accordance with section 4729.13 of the Revised Code, a pharmacist who fails to renew a license within three years may reinstate the license by:

(1) Successfully completing the required examinations pursuant to rule 4729:1-2-01 of the Administrative Code; or

(2) Meeting the criteria for licensure by reciprocity pursuant to rule 4729:1-2-02 of the Administrative Code.

(H) A pharmacist applying for reinstatement pursuant to paragraph (G) shall submit the following to the state board of pharmacy:

(1) A completed application form as provided by the board;

(2) Required fee, including any transaction fee as required by section 125.18 of the Revised Code;

(3) Criminal records check as required by rule 4729:1-2-05 of the Administrative Code; and

(4) The applicable registration or license transfer applications as determined by the national association of boards of pharmacy (NABP).

Last updated March 4, 2024 at 8:40 AM

History

Effective: March 4, 2024
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-2-08 Veteran and military family provisions related to pharmacist licensure.

(A) Renewal of an expired license.

(1) In accordance with section 5903.10 of the Revised Code, a holder of an expired license shall be granted a renewal of the license by the state board of pharmacy at the usual cost without penalty and without re-examination if not otherwise disqualified because of mental or physical disability and if either of the following applies:

(a) The license was not renewed because of the holder's service in the armed forces.

(b) The license was not renewed because the holder's spouse served in the armed forces of the United States or a reserve component of the armed forces and the service resulted in the holder's absence from this state.

(2) A pharmacist shall submit proper documentation certifying the active duty service and length of active duty service. Documentation required to obtain a renewal pursuant to paragraph (A)(1) of this rule will be published on the state board of pharmacy's website: www.pharmacy.ohio.gov.

(B) The state board of pharmacy may implement fee waivers for licensure. If implemented, fee waivers will be published on the state board of pharmacy's web site: www.pharmacy.ohio.gov.

In accordance with section 5903.03 of the Revised Code, there are no military programs of training or military primary specialties which are substantially equivalent to the education requirements for licensure as a pharmacist.

Last updated January 3, 2024 at 12:17 PM

History

Effective: March 1, 2018
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-2-10 Emeritus pharmacists.

(A) As used in this rule:

(1) "Emeritus pharmacist" means an individual who meets all the following:

(a) Is currently or has been licensed to practice pharmacy in this state for at least ten years;

(b) Is retired from the practice of pharmacy;

(d) Is at least sixty years old or has held a license to practice pharmacy in Ohio for at least thirty years; and

(e) Has applied for an emeritus designation in accordance with this rule.

(2) "In good standing" means a pharmacist to which all the following apply at the time of application:

(a) Does not have a board order restricting the privilege of supervising interns;

(b) Has not been denied a license, registration or certificate by any public agency or licensing agency;

(c) Does not have a license, registration or certificate limited, suspended, or revoked by any public agency or licensing agency.

(B) Any person that meets the requirements in paragraph (A)(1) of this rule may apply to the board for emeritus designation.

(C) To apply for emeritus designation, a pharmacist shall submit a form containing information as required by the board and in a manner determined by the board.

(D) There shall be no fee associated with applying for or maintaining an emeritus designation.

(E) The emeritus designation is not a license to engage in the practice of pharmacy.

(1) Emeritus pharmacists shall not engage in the practice of pharmacy.

(2) Upon issuance of an emeritus designation, a license authorizing the person to practice pharmacy shall be considered void and may only be renewed or reinstated in accordance with the provisions of Chapter 4729. of the Revised Code and this chapter of the Administrative Code.

(F) The continuing education requirements of Chapter 4729:1-5 of the Administrative Code are not applicable to an emeritus pharmacist.

(G) An emeritus pharmacist shall not be subject to the licensure renewal requirements or renewal fees pursuant to this chapter.

(H) The board may refuse to issue or may revoke an emeritus designation for acts or conduct that are in violation of any provision of Chapters 4729., 3719., 3796., 3715., and 2925. of the Revised Code or Chapter 4729:1-4 of the Administrative Code. The decision to refuse to issue or revoke an emeritus designation is not subject to hearing rights or appeal under Chapter 119. of the Revised Code.

Last updated May 15, 2026 at 7:31 AM

History

Effective: May 15, 2026
Promulgated Under: 119.03

Chapter 4729:1-3 Practice

Ohio Adm.Code 4729:1-3-01 Pharmacist administration of diagnostic tests.

(A) A pharmacist may administer clinical laboratory improvement amendments (CLIA) waived diagnostic laboratory testing provided the following conditions are met:

(1) The pharmacy or facility licensed as a terminal distributor of dangerous drugs is certified by the United States department of health and human services (HHS), as a clinical laboratory through the CLIA;

(2) The pharmacy or facility licensed as a terminal distributor of dangerous drugs has obtained a CLIA certificate of waiver from HHS; and

(3) The responsible person of the terminal distributor of dangerous drugs and the terminal distributor of dangerous drugs ensures and documents that all pharmacists conducting CLIA waived tests pursuant to this rule receive appropriate training to conduct testing in a safe and effective manner.

(B) A pharmacist may evaluate the results of a test administered under this rule when advising a patient or a health care professional treating a patient if the test relates to the patient's drug therapy.

(C) This rule applies only to the administration and evaluation of laboratory testing by individuals licensed or registered in accordance with Chapter 4729. of the Revised Code.

Last updated October 22, 2025 at 11:13 AM

History

Effective: January 1, 2020
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-3-02 Immunization administration.

(A) A course in the administration of immunizations developed pursuant to division (B) of section 4729.41 of the Revised Code shall meet the following requirements:

(1) The instructor shall be a licensed health care professional and have the appropriate education and experience to teach a course in the administration of immunizations.

(2) The content must meet the standards established for such courses by the centers for disease control and prevention in the public health service of the United States department of health and human services.

(3) The course shall be conducted by an accreditation council for pharmacy education (ACPE) accredited provider.

(4) The course must be a minimum of five hours in length and include the following:

(a) A review of immunology that includes a discussion of the body's immune system reaction to immunizations.

(b) A review of each immunization recommended by the advisory committee on immunization practices of centers for disease control and prevention in the United States department of health and human services (6/28/2024) that includes the following:

(i) Disease states associated with the immunization;

(ii) Type or nature of activity of the immunization;

(iii) Administration schedules;

(iv) Routes of administration;

(v) Injection sites;

(vi) Dosages;

(vii) Monitoring and treatment of the patient for adverse reactions, including the use of diphenhydramine and epinephrine;

(viii) Patient populations;

(ix) Precautions and contraindications; and

(x) Proper storage requirements for the immunization.

(d) A minimum of one hour of instruction and physical participation in administration techniques.

(e) A review of the proper disposal procedures for contaminated needles and immunizations.

(f) A review of the proper procedures for accidental needle sticks.

(5) The course must provide a method to evaluate the successful comprehension of the content.

(6) The course must provide a method to demonstrate the participant has successfully completed the course.

(B) Courses on immunization administration may be reviewed by the state board of pharmacy. A training course that fails to comply with the requirements set forth in this rule shall be considered in violation of this rule.

(C) Failure to adhere to the standard of care for administration of an immunization shall be considered a violation of this rule and may subject a pharmacist to discipline in accordance with rule 4729:1-4-01 of the Administrative Code.

(D) Pursuant to section 4729.41 of the Revised Code, a prescriber-established protocol for the administration of immunizations shall include the following:

(1) For each immunization authorized:

(a) Name and strength;

(b) Precautions and contraindications;

(d) Dosage;

(e) Administration schedules;

(f) Routes of administration; and

(g) Injection sites.

(2) The length of time the pharmacist, pharmacy intern, certified pharmacy technician, or registered pharmacy technician under the direct supervision of a pharmacist must observe an individual for adverse effects, which shall be based on appropriate standards of care established by the authorizing prescriber. The location of the observation shall be in the general vicinity of the administering pharmacist, pharmacy intern, certified pharmacy technician, or registered pharmacy technician to allow for on-going evaluation.

(3) A method to address emergency situations including, but not limited to, adverse reactions, anaphylactic reactions, and accidental needle sticks.

(4) A method to notify an individual's primary care provider or the applicable board of health within thirty days after administering an immunization, except for influenza immunizations administered to individuals eighteen years of age and older.

(5) The locations that a pharmacist, pharmacy intern, certified pharmacy technician, or registered pharmacy technician under the direct supervision of a pharmacist may engage in the administration of immunizations.

(E) All prescriber-established protocols must be signed and dated by the prescriber prior to implementation and maintained by the terminal distributor of dangerous drugs. The protocols shall be renewed by a prescriber on a biennial basis.

(1) A prescriber may sign one protocol for multiple locations licensed as terminal distributors of dangerous drugs.

(2) Each location licensed as a terminal distributor of dangerous drugs shall maintain a copy of the protocol on-site for inspection by an agent, inspector, or employee of the state board of pharmacy.

(F) Upon the request of the state board of pharmacy, a pharmacist or terminal distributor of dangerous drugs shall immediately provide the protocols for immunizations. The state board of pharmacy, after review, may approve the protocol or return it to the pharmacist or terminal distributor for revision without approval. If a protocol has been returned for revision without approval, it may not be implemented until the board has granted approval.

(G) A pharmacist, in accordance with section 4729.41 of the Revised code and this rule, may administer to an individual who is five years of age or older an immunization for any disease, including an immunization for influenza or COVID-19.

(H) A pharmacist shall obtain informed consent pursuant to rule 4729:5-5-04 of the Administrative Code to administer an immunization.

(I) Immunization records shall be maintained in accordance with rule 4729:5-5-04 of the Administrative Code.

(J) A pharmacist shall comply with the vaccine information statement requirements of the National Vaccine Childhood Injury Act, 42 USC Section 300aa-26 (12/14/1993).

(K) For each immunization administered to an individual by a pharmacist, other than an immunization for influenza administered to an individual eighteen years of age or older, the pharmacist shall notify the individual's primary care provider or, if the individual has no primary care provider, the board of health of the health district in which the individual resides or the authority having the duties of a board of health for that district under section 3709.05 of the Revised Code. The notice shall be given not later than thirty days after the immunization is administered. Notification shall be conducted using one of the following methods that is capable of confirming delivery of the required notification:

(1) Electronic mail;

(2) Interoperable electronic medical records system;

(3) Facsimile;

(4) Electronic prescribing system;

(5) Electronic pharmacy record system;

(6) Documented verbal communication;

(7) Reporting to the state's immunization registry; or

(8) Any other method of notification that might reasonably be expected to allow for the confirmed transmission of the required notification.

(L) For each immunization administered by a pharmacist to an individual who is younger than eighteen years of age, the pharmacist shall inform the individual's parent or legal guardian of the importance of well child visits with a pediatrician or other primary care provider and shall refer patients when appropriate.

(M) A pharmacist administering immunizations in accordance with this rule shall receive and maintain certification to perform basic life-support procedures by successfully completing a basic life-support training course certified by the American red cross, American heart association, American safety and health institute, or other training course approved by the board. Certification shall be obtained and maintained through courses that are conducted in-person or, at a minimum, offer an in-person or electronic hands-on training component.

(N) A pharmacist who completed a course in the administration of immunizations that complied with the training requirements in effect immediately prior to the adoption of this rule shall be deemed in compliance with division (B)(1) of section 4729.41 of the Revised Code.

(O) A pharmacist shall maintain the following records on file at the location(s) where the pharmacist administers immunizations in accordance with this rule:

(1) Proof of successful completion of a training course specified in paragraph (A) of this rule; and

(2) Proof of maintenance of certification to perform basic life-support procedures in accordance with paragraph (M) of this rule.

(P) As part of engaging in the administration of immunizations or supervising an individual authorized to administer immunizations, a pharmacist may administer epinephrine or diphenhydramine, or both, to individuals in emergency situations resulting from adverse reactions to the immunizations administered by the pharmacist or other authorized individuals under the supervision of the pharmacist.

(Q) As used in this rule, "prescriber" means either:

(1) A physician authorized under Chapter 4731. of the Revised Code to practice medicine and surgery or osteopathic medicine and surgery; or

(2) A certified nurse-midwife, clinical nurse specialist, or certified nurse practitioner licensed under Chapter 4723. of the Revised Code.

Last updated May 19, 2025 at 7:58 AM

History

Effective: May 19, 2025
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-4-01

(A) As used in this rule:

(1) "Dishonesty" means any action by a licensee, registrant or applicant to include, but is not limited to, making any statement that deceives, misrepresents or misleads, or be a party to or an accessory to any fraudulent or deceitful practice or transaction in the practice of pharmacy or in the operation or conduct of a pharmacy.

(2) "Unprofessional conduct" has the same meaning as defined in division (C) of section 4729.16 of the Revised Code and shall also include conduct that is detrimental to the best interests of the public, including conduct that endangers the health, safety or welfare of a patient or client. Such conduct shall include, but not be limited to, the following acts: coercion, intimidation, harassment, sexual harassment, improper use of private health information, threats, degradation of character, indecent or obscene conduct, and theft.

(3) "Reckless behavior" means a person who acts recklessly or who is reckless. A person acts recklessly when, with heedless indifference to the consequences, the person disregards a substantial and unjustifiable risk that the person's conduct is likely to cause a certain result or is likely to be of a certain nature. A person is reckless with respect to circumstances when, with heedless indifference to the consequences, the person disregards a substantial and unjustifiable risk that such circumstances are likely to exist.

(B)

(1) The state board of pharmacy, after notice and hearing in accordance with Chapter 119. of the Revised Code, may impose any one or more of the following sanctions on a pharmacist or applicant for a pharmacist license if the board finds the individual engaged in any of the conduct set forth in paragraph (B)(2) of this rule:

(a) Revoke, suspend, restrict, limit, or refuse to grant or renew a license;

(b) Reprimand or place the license holder on probation;

(c) Impose a monetary penalty or forfeiture not to exceed in severity any fine designated under the Revised Code for a similar offense, or in the case of a violation of a section of the Revised Code that does not bear a penalty, a monetary penalty or forfeiture of not more than five hundred dollars.

(2) The board may impose the sanctions listed in paragraph (B)(1) of this rule if the board finds a pharmacist or applicant for a pharmacist license:

(a) Has a criminal conviction for, judicial finding of guilt of, or plea of guilty to a disqualifying offense.

(b) Engaged in dishonesty or unprofessional conduct in the practice of pharmacy.

(c) Is addicted to or abusing alcohol or drugs or is impaired physically or mentally to such a degree as to render the pharmacist unfit to practice pharmacy.

(d) Except as provided for in paragraph (B)(2)(r) of this rule, violated, conspired to violate, attempted to violate, or aided and abetted the violation of any of the provisions of Chapter 4729. of the Revised Code, sections 3715.52 to 3715.72 of the Revised Code, Chapter 2925., 3796., 3719. or 4752. of the Revised Code, or any rule adopted by the board under those provisions.

(e) Permitted someone other than a pharmacist or pharmacy intern to practice pharmacy.

(f) Knowingly lent the pharmacist's name to an illegal practitioner of pharmacy or had a professional connection with an illegal practitioner of pharmacy.

(g) Divided or agreed to divide remuneration made in the practice of pharmacy with any other individual, including, but not limited to, any licensed health professional authorized to prescribe drugs or any owner, manager, or employee of a health care facility, residential care facility, or nursing home.

(h) Violated the terms of a consult agreement entered into pursuant to section 4729.39 of the Revised Code.

(i) Committed fraud, misrepresentation, or deception in applying for or securing a license issued by the board under this chapter or under Chapter 3796., 3715., 3719. or 4752. of the Revised Code.

(j) Failed to comply with an order of the board or a settlement agreement.

(k) Violated any state or federal law, regulation or rule regardless of the jurisdiction in which the acts were committed, except for minor traffic violations such as parking violations, speeding tickets and violations such as failure to obey a red light, failure to use a turn signal or expired vehicle registration.

(l) Has been disciplined by the state board of pharmacy pursuant to section 4729.16 of the Revised Code.

(m) Has been the subject of any of the following by the drug enforcement administration or licensing agency of any state or jurisdiction:

(i) A disciplinary action that resulted in the suspension, probation, surrender or revocation of the person's license or registration.

(ii) A disciplinary action that was based, in whole or in part, on the person's inappropriate prescribing, dispensing, diverting, administering, storing, securing, personally furnishing, compounding, supplying or selling a controlled substance or other dangerous drug.

(n) Failed to conform to prevailing standards of care of similar pharmacists under the same or similar circumstances, whether or not actual injury to a patient is established.

(o) Has been subject to any of the following:

(i) A finding by a court of the person's eligibility for intervention in lieu of conviction; or

(ii) A finding by a court of the person's eligibility for treatment or intervention in lieu of conviction in another jurisdiction.

(p) Has been granted entry into a diversion program, deferred prosecution program, or the equivalent thereof.

(q) Cannot practice according to acceptable and prevailing standards of care by reason of mental illness or physical illness, including, but not limited to, physical deterioration that adversely affects cognitive, motor, or perceptive skills.

(r) Is responsible for any of the following but only as a result of reckless behavior:

(i) An error in dispensing as defined in rule 4729:5-3-22 of the Administrative Code;

(ii) A product quality issue for any compounded drug preparation as defined in rule 4729:7-2-03 of the Administrative Code.

Last updated March 4, 2025 at 7:59 AM

History

Effective: March 1, 2025
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-3-03 Administration of dangerous drugs by injection.

(A) A pharmacist licensed under Chapter 4729. of the Revised Code may administer by subcutaneous or intramuscular injection any of the following drugs as long as the drug that is to be administered has been prescribed by a physician, certified nurse-midwife, clinical nurse specialist, or certified nurse practitioner and the individual to whom the drug was prescribed has an ongoing physician-patient or nurse-patient relationship with the physician or nurse:

(1) An addiction treatment drug administered in a long-acting or extended-release form, which may include any medication indicated for relapse prevention;

(2) An antipsychotic drug administered in a long-acting or extended-release form;

(3) A human immunodeficiency virus treatment or prevention drug administered in a long-acting or extended-release form;

(4) Hydroxyprogesterone caproate for pregnant women;

(5) Medroxyprogesterone acetate for non-pregnant women;

(6) Cobalamin, to include: cyanocobalamin, hydroxocobalamin or any other vitamin B12 injection approved by the United States food and drug administration;

(7) Antibiotics;

(8) Denosumab or romosozumab;

(9) Methotrexate for non-emergent conditions;

(10) Heparin, low molecular weight heparin, and factor Xa inhibitors; and

(11) Any other dangerous drugs authorized for pharmacist administration pursuant to section 4729.45 of the Revised Code.

(B) To be authorized to administer drugs pursuant to this rule, a pharmacist shall comply with all the following:

(1) Successfully complete a course in the administration of drugs that satisfies the requirements pursuant to paragraph (L) of this rule.

(2) Receive and maintain certification to perform basic life-support procedures by successfully completing a basic life-support training course certified by the American red cross, American heart association, American safety and health institute, or other training course approved by the board. Certification shall be obtained and maintained through courses that are conducted in-person or, at a minimum, offer an in-person training component.

(3) Practice in accordance with a protocol that meets the requirements of paragraphs (F) and (G) of this rule.

(1) For each drug administered by a pharmacist to an individual who is eighteen years of age or older, the pharmacist shall obtain written permission from the individual.

(2) For each drug administered by a pharmacist to an individual who is under eighteen years of age, the pharmacist shall obtain written permission from the individual's parent or other person having care or charge of the individual.

(3) For each drug administered by a pharmacist to an individual who lacks the capacity to make informed health care decisions, the pharmacist shall obtain written permission from the person authorized to make such decisions on the individual's behalf.

(4) Permission obtained in accordance with this paragraph shall also include notification of the patient's right to request a private area or chaperone in accordance with paragraph (J) of this rule.

(5) In the case of an addiction treatment drug described in paragraph (A)(1) of this rule, obtain, in accordance with paragraph (D) of this rule, test results indicating that it is appropriate to administer the drug to the individual if either of the following is to be administered:

(a) The initial dose of the drug;

(b) Any subsequent dose, if the administration occurs more than thirty days after the previous dose of the drug was administered.

(6) Observe the individual to whom the drug is administered to determine whether the individual has an adverse reaction to the drug.

(7) Notify the physician, certified nurse-midwife, clinical nurse specialist, or certified nurse practitioner who prescribed the drug within seven days that the drug has been administered to the individual. Notification shall be conducted using one of the following methods that is capable of confirming delivery of the required notification:

(a) Electronic mail;

(b) Interoperable electronic medical records system;

(d) Electronic prescribing system;

(e) Electronic pharmacy record system;

(f) Documented verbal communication; or

(g) Any other method of notification that might reasonably be expected to allow for the confirmed transmission of the required notification.

(D) A pharmacist may obtain the test results described in paragraph (C)(5) of this rule:

(1) From the prescribing physician, certified nurse-midwife, clinical nurse specialist, certified nurse practitioner;

(2) From an agent of the prescribing physician, certified nurse-midwife, clinical nurse specialist, certified nurse practitioner; or

(3) By ordering blood and urine tests for the individual to whom the addiction treatment drug is to be administered.

(E) If a pharmacist orders blood and urine tests pursuant to paragraph (D) of this rule, the pharmacist shall evaluate the results of the tests to determine whether they indicate that it is appropriate to administer the addiction treatment drug. A pharmacist's authority to evaluate test results pursuant to this rule does not authorize the pharmacist to make a diagnosis.

(F) A protocol for the administration of dangerous drugs in accordance with section 4729.45 of the Revised Code shall include the following:

(1) For the dangerous drugs listed in paragraph (A) of this rule:

(a) Name and strength;

(b) Precautions and contraindications;

(d) Dosage;

(e) Administration schedules;

(f) Routes of administration;

(g) Injection sites;

(h) The type of tests that may be ordered in accordance with paragraph (E) of this rule;

(i) Any special handling instructions or precautions, if applicable.

(2) The length of time the pharmacist must observe an individual for adverse effects, which shall be based on standards of care established by the authorizing physician, certified nurse-midwife, clinical nurse specialist, or certified nurse practitioner. The location of the observation shall be in the general vicinity of the administering pharmacist to allow for on-going evaluation.

(3) A method to address emergency situations including, but not limited to, adverse reactions, anaphylactic reactions, and accidental needle sticks.

(4) The locations that a pharmacist shall engage in the administration of dangerous drugs in accordance with paragraph (J) of this rule.

(5) Specify procedures to be followed by a pharmacist when administering epinephrine, diphenhydramine, or both, to an individual who has an adverse reaction to a drug administered by the pharmacist.

(G) All protocols pursuant to this rule and section 4729.45 of the Revised Code shall comply with the following:

(1) The protocol shall be signed and dated by the authorizing physician, certified nurse-midwife, clinical nurse specialist, or certified nurse practitioner prior to implementation and shall be readily available to the administering pharmacist. The protocol shall be renewed by the physician on a biennial basis.

(2) A physician, certified nurse-midwife, clinical nurse specialist, or certified nurse practitioner may sign one protocol for multiple locations licensed as terminal distributors of dangerous drugs.

(3) Each location licensed as a terminal distributor of dangerous drugs shall maintain a copy of the protocol on-site for immediate inspection by an agent, inspector, or employee of the state board of pharmacy.

(4) The protocol must be established by a physician, certified nurse-midwife, clinical nurse specialist, or certified nurse practitioner who has a scope of practice that includes treatment of the condition for which the individual has been prescribed the drug to be administered.

(H) Upon the request of the state board of pharmacy, a pharmacist or terminal distributor of dangerous drugs shall immediately provide the protocols for administration of drugs in accordance with this rule. The state board of pharmacy, after review, may approve the protocol or return it to the pharmacist or terminal distributor for revision without approval. If a protocol has been returned for revision without approval, it may not be implemented until the board has granted approval.

(I) A pharmacist may administer epinephrine or diphenhydramine, or both, to an individual in an emergency situation resulting from an adverse reaction to a drug administered by the pharmacist.

(J) Dangerous drugs administered in accordance with this rule shall be administered in a location that ensures the privacy and dignity of the patient and is consistent with state and federal privacy laws and regulations. When necessary to protect patient privacy, or if requested by the patient, this shall include a private area located outside of the pharmacy.

For all dangerous drugs requiring administration in the gluteal muscle or any other administration requiring the removal of clothing, the administering pharmacist shall:

(1) Offer a chaperone to patients and/or provide a chaperone upon the patient's request;

(2) Employ disrobing, draping, and positioning practices that protect a patient's privacy and dignity; and

(3) Administer in a private area and minimize patient exposure by only exposing the specific injection site.

(K) Administration records shall be maintained in accordance with rule 4729:5-5-04 of the Administrative Code.

(L) A course in the administration of dangerous drugs developed pursuant to section 4729.45 of the Revised Code shall meet the following requirements:

(1) The course shall be conducted by an accreditation council for pharmacy education (ACPE) accredited provider.

(2) The course must include the following components:

(a) A minimum of five hours (0.5 C.E.U.s) of live or home study coursework forthe dangerous drugs listed in paragraph (A) of this rule that is covered by the course and shall include:

(i) A review of the conditions treated or prevented;

(ii) Mechanisms of action;

(iii) Routes of administration;

(iv) Injection sites and ensuring patient privacy;

(v) Dosages and administration schedules;

(vi) Monitoring and treatment of the patient for adverse reactions, including the use of diphenhydramine and epinephrine;

(vii) Patient populations;

(viii) Precautions and contraindications; and

(ix) Proper storage requirements.

(b) A minimum of thirty minutes (0.05 C.E.U.s) of live or home study coursework that includes:

(i) A review of sterile technique in injectable dosage preparation and administration;

(ii) A review of the proper disposal procedures for contaminated needles and dangerous drugs; and

(iii) A review of the proper procedures for accidental needle sticks.

(c) A minimum of one hour (0.1 C.E.U.s) of live and supervised physical participation in subcutaneous and intramuscular administration techniques.

(3) The course must provide a method to evaluate the successful comprehension of the content.

(4) The course must provide a method to demonstrate the pharmacist has successfully completed the course.

(5) All live coursework shall be taught by an instructor that is a licensed health care professional who has the appropriate education and experience to teach a course in the administration of the dangerous drugs included in the categories listed in paragraph (A) of this rule.

(M) Courses may be reviewed by the state board of pharmacy. A training course that fails to comply with the requirements set forth in this rule shall be considered in violation of this rule.

(N) A pharmacist who has not successfully completed a course in drug administration that meets the requirements set forth in this rule must complete a course that meets the requirements specified in this rule prior to the administration of a dangerous drug listed in paragraph (A) of this rule.

(O) A pharmacist shall maintain the following records on file at the location(s) where the pharmacist administers dangerous drugs in accordance with this rule:

(1) Proof of successful completion of a training course specified in paragraph (L) of this rule; and

(2) Proof of maintenance of certification to perform basic life-support procedures in accordance with paragraph (B)(2) of this rule.

(P) A pharmacist shall not intravenously administer any drug listed in paragraph (A) of this rule.

(Q) Failure to adhere to the standard of care for the administration of a dangerous drug listed in paragraph (A) of this rule shall be considered a violation of this rule and may subject a pharmacist to discipline in accordance with rule 4729:1-4-01 of the Administrative Code.

(R) A pharmacist who completed a course in the administration of drugs that complied with the training requirements in effect immediately prior to the adoption of this rule shall be deemed to have met the training required by section 4729.45 of the Revised Code.

Last updated January 7, 2026 at 7:34 AM

History

Effective: January 7, 2026
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-3-04 Dispensing of naloxone by pharmacists.

(A) A pharmacist may dispense naloxone without a prescription to either of the following in accordance with a protocol specified in paragraph (B) of this rule:

(1) An individual who there is reason to believe is experiencing or at risk of experiencing an opioid-related overdose;

(2) A family member, friend, or other person in a position to assist an individual who there is reason to believe is at risk of experiencing an opioid-related overdose.

(B) A physician-established protocol for the dispensing of naloxone by a pharmacist or pharmacy intern under the direct supervision of a pharmacist shall include, but is not limited to, the following:

(1) A description of the clinical pharmacology of naloxone.

(2) Indications for use of naloxone as rescue therapy, including criteria for identifying persons eligible to receive naloxone under the protocol.

(3) Precautions and contraindications concerning dispensing naloxone.

(4) Naloxone products authorized to be dispensed, including all of the following information:

(a) Name of product;

(b) Dose;

(d) Directions for use.

(5) Any patient instructions in addition to the patient training specified in this rule and rule 4729:2-3-04 of the Administrative Code.

(C) A pharmacist who dispenses naloxone pursuant to this rule shall instruct the individual to whom naloxone is dispensed verbally or in writing to summon emergency services as soon as practicable either before or after administering naloxone.

(D) Except as provided in paragraph (E) this rule, a pharmacist or a pharmacist's designee that is appropriately trained shall provide in-person training, unless the in-person training requirement is waived by the board, and written educational materials to the individual to whom naloxone is dispensed that includes all the following:

(1) Risk factors of opioid overdose;

(2) Strategies to prevent opioid overdose;

(3) Signs of opioid overdose;

(4) Steps in responding to an overdose;

(5) Information on the naloxone dispensed;

(6) Procedures for administering the naloxone dispensed;

(7) Proper storage and expiration of the naloxone dispensed; and

(8) Information on where to obtain a referral for substance abuse treatment.

(E) Patient training as required by paragraph (D) of this rule is not required if the patient has previously received training and all the following apply:

(1) The patient is offered training and refuses;

(2) The pharmacist or pharmacist designee has documentation confirming training pursuant to this rule has been provided within the previous twelve months;

(3) A pharmacist who dispenses naloxone pursuant to this rule shall still instruct the individual to whom naloxone is dispensed verbally or in writing to summon emergency services as soon as practicable either before or after administering naloxone.

(F) If training conducted pursuant to paragraph (D) of this rule is offered by a pharmacist's designee, the pharmacist shall not be required to counsel a patient or caregiver pursuant to rule 4729:5-5-09 of the Administrative Code if the patient or caregiver refuses the offer of counseling or does not respond to the written offer to counsel.

(G) A terminal distributor of dangerous drugs shall ensure that all pharmacists that dispense naloxone pursuant to this rule are trained on the use of naloxone and can meet the training requirements listed in paragraphs (C) and (D) of this rule.

(H) A terminal distributor of dangerous drugs shall ensure that all pharmacist designees are trained on the use of naloxone and can meet the training requirements listed in paragraph (D) of this rule.

(I) A pharmacist may document on a prescription form the dispensing of naloxone by the pharmacist or a pharmacy intern supervised by the pharmacist. The form may be assigned a number for record-keeping purposes.

(J) All physician-established protocols must be signed and dated by the physician prior to implementation and maintained by the terminal distributor of dangerous drugs. The protocols shall be renewed by a physician on a biennial basis.

(1) A physician may sign one protocol for multiple locations licensed as terminal distributors of dangerous drugs.

(2) Each location licensed as a terminal distributor of dangerous drugs shall maintain a copy of the protocol on-site for inspection by an agent, inspector or employee of the state board of pharmacy.

(K) Any pharmacy that dispenses naloxone pursuant to section 4729.44 of the Revised Code shall notify the board, in a manner determined by the board, within thirty days of establishing a protocol. A pharmacy that no longer dispenses naloxone pursuant to section 4729.44 of the Revised Code shall notify the board, in a manner determined by the board, within thirty days of discontinuation.

(1) Except in the event of a drug shortage, a pharmacy submitting notification of naloxone dispensing shall ensure naloxone is made available in accordance with this rule.

(2) A pharmacy that has submitted notification of naloxone dispensing shall provide initial training to all new employees and annual training to existing employees on the availability of naloxone dispensing pursuant to a protocol. Employees requiring training in accordance with this paragraph shall include: pharmacists, pharmacy interns, certified pharmacy technicians, registered pharmacy technicians, pharmacy technician trainees, and support personnel, as defined in rule 4729:3-1-01 of the Administrative Code, that have direct contact with the public. Training documentation records shall be maintained for a period of three years and shall be made readily retrievable.

(L) Paragraph (K) of this rule does not apply to institutional pharmacies that provide naloxone to inpatients or patients upon discharge.

Last updated June 11, 2026 at 11:17 AM

History

Effective: December 1, 2020
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-3-05 Therapeutic diabetic shoes.

(A) Pursuant to section 4779.02 of the Revised Code, a pharmacist may fit and measure individuals for therapeutic diabetic shoes and shoe inserts and may dispense those shoes and shoe inserts.

(B) A pharmacist shall not provide any other services that are authorized under Chapter 4779. of the Revised Code.

Last updated April 15, 2024 at 1:33 PM

History

Effective: April 1, 2019
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-3-06 Dispensing of epinephrine autoinjectors by pharmacists.

(A) A pharmacist may dispense an epinephrine autoinjector without a prescription to either of the following in accordance with a protocol specified in paragraph (B) of this rule:

(1) An individual who there is reason to believe is experiencing or at risk of experiencing anaphylaxis if the pharmacy affiliated with the pharmacist has a record of previously dispensing epinephrine to the individual in accordance with a prescription issued by a licensed health professional authorized to prescribe drugs; or

(2) An individual acting on behalf of a qualified entity, as defined in section 3728.01 of the Revised Code.

(B) A physician-established protocol for the dispensing of epinephrine autoinjectors by a pharmacist or pharmacy intern under the direct supervision of a pharmacist shall include, but is not limited to, the following:

(1) Indications for use of epinephrine autoinjectors, including criteria for identifying persons eligible to receive an autoinjector under the protocol.

(2) Precautions and contraindications related to the dispensing of epinephrine autoinjectors.

(3) Epinephrine autoinjectors authorized to be dispensed, including all the following information:

(a) Name of product;

(b) Dose;

(d) Directions for use.

(4) Any patient instructions in addition to the training specified in this rule and rule 4729:2-3-06 of the Administrative Code.

(C)

(1) A pharmacist who dispenses an epinephrine autoinjector pursuant to this rule shall instruct the individual to whom the epinephrine autoinjector is dispensed, either verbally or in writing, to summon emergency services as soon as practicable either before or after administering epinephrine.

(2) A pharmacist who dispenses an epinephrine autoinjector to an individual identified in paragraph (A) of this rule shall provide notification of the dispensing to the individual's primary care provider, if known, or to the prescriber who issued the individual the initial prescription for an epinephrine autoinjector. Notification shall be conducted using one of the following methods that is capable of confirming delivery of the required notification:

(a) Electronic mail;

(b) Interoperable electronic medical records system;

(d) Electronic prescribing system;

(e) Electronic pharmacy record system;

(f) Documented verbal communication;

(g) Any other method of notification that might reasonably be expected to allow for the confirmed transmission of the required notification.

(D) When a pharmacist dispenses an epinephrine autoinjector pursuant to this rule, the pharmacist, or pharmacy intern under the direct supervision of a pharmacist, shall provide to the person receiving the device instruction on the proper method of administering epinephrine with the device.

(E) A terminal distributor of dangerous drugs shall ensure that all pharmacists that dispense epinephrine autoinjectors pursuant to this rule are trained on the use of epinephrine and can meet the training requirements listed in paragraphs (C) and (D) of this rule.

(F) A pharmacist may document the dispensing of an epinephrine autoinjector by the pharmacist or pharmacy intern under the direct supervision of the pharmacist on a prescription form. The form may be assigned a number for record-keeping purposes.

(G) This rule does not affect the authority of a pharmacist to:

(1) Dispense a new prescription or refill for epinephrine; or

(2) Contact a prescriber to obtain a new oral prescription for an epinephrine autoinjector in accordance with the applicable provisions of division 4729:5 of the Administrative Code.

(H) All physician-established protocols must be signed and dated by the physician prior to implementation and maintained by the terminal distributor of dangerous drugs. The protocols shall be renewed by a physician on a biennial basis.

(1) A physician may sign one protocol for multiple locations licensed as terminal distributors of dangerous drugs.

(2) Each location licensed as a terminal distributor of dangerous drugs shall maintain a copy of the protocol on-site for inspection by an agent, inspector or employee of the state board of pharmacy.

Last updated May 19, 2026 at 3:52 PM

History

Effective: January 18, 2020
Promulgated Under: 119.03

Ohio Adm.Code 4729:1-3-07 Dispensing nicotine replacement therapy by pharmacists.

(A) As used in this rule, "nicotine replacement therapy" means a drug, including a dangerous drug, that delivers small doses of nicotine to an individual for the purpose of aiding in tobacco cessation or smoking cessation including for the cessation of alternative nicotine delivery systems, such as e-cigarettes.

(B) A pharmacist may dispense nicotine replacement therapy to individuals who are eighteen years old or older and seeking to quit using tobacco-containing products in accordance with paragraph (C) of this rule.

(C) For a pharmacist to be authorized to dispense nicotine replacement therapy under this rule, the pharmacist shall do both of the following:

(1) Successfully complete a course on nicotine replacement therapy that is taught by a provider that is accredited by the accreditation council for pharmacy education, or another provider approved by the state board of pharmacy, and that meets requirements established in paragraph (H) of this rule; and

(2) Practice in accordance with a physician-authorized protocol that meets the requirements of paragraph (D) of this rule.

(D) All of the following apply with respect to the protocol required by this rule:

(1) The protocol shall be established by a physician authorized under Chapter 4731. of the Revised Code to practice medicine and surgery or osteopathic medicine and surgery.

(2) The protocol shall specify a definitive set of treatment guidelines and the locations at which a pharmacist may dispense nicotine replacement therapy under this rule.

(3) The protocol shall specify the types of nicotine replacement therapy that may be dispensed.

(4) The protocol shall include provisions for implementation of the following requirements:

(a) Use by the pharmacist of a screening procedure, recommended by the United States centers for disease control and prevention or another organization approved by the board, to determine if an individual is a good candidate to receive nicotine replacement therapy dispensed as authorized by this rule;

(b) A requirement that the pharmacist refer high-risk individuals, as defined in the protocol, or individuals with contraindications to a primary care provider or, as appropriate, to another type of provider;

(c) A requirement that the pharmacist develop and implement a follow-up care plan in accordance with paragraph (D)(5) of this rule, including a recommendation by the pharmacist that the individual seek additional assistance with behavior change, including assistance from the Ohio tobacco quit line made available by the department of health.

(5) A follow-up care plan shall include all the following:

(a) A recommendation that the individual notify their provider that they have initiated a quit attempt;

(b) A plan to deal with the psychological aspects of tobacco addiction, including information regarding how to seek services from the Ohio tobacco quit line;

(d) Instructions regarding how, when, and how many times to refill the medication;

(e) Follow-up with patient should occur within a clinically appropriate length of time after the initiation of the nicotine replacement therapy as deemed appropriate by the pharmacist;

(f) How and when to stop using nicotine replacement therapy;

(g) Instructions to seek assistance from the pharmacist or provider before continuing to use the medication if a relapse occurs and tobacco use is reinitiated;

(h) If a patient returns to the pharmacy to report a relapse, the follow-up care plan should include efforts to identify smoking cues and triggers and decide upon alternative coping strategies before a follow-up attempt to quit tobacco;

(i) If dual therapy is indicated for the patient, instructions to seek assistance from a prescribing provider to add prescription-only smoking cessation medication to the pharmacist-initiated nicotine replacement therapy.

(6) All physician-established protocols must be signed and dated by the physician prior to implementation and maintained by the terminal distributor of dangerous drugs. The protocols shall be renewed by a physician on a biennial basis.

(a) A physician may sign one protocol for multiple locations licensed as terminal distributors of dangerous drugs.

(b) Each location licensed as a terminal distributor of dangerous drugs shall maintain a copy of the protocol on-site for inspection by an agent, inspector, or employee of the state board of pharmacy.

(E)

(1) Documentation related to screening, dispensing, and follow-up care plans shall be maintained in the records of the terminal distributor of dangerous drugs where the pharmacist practices for at least three years. Dispensing of nicotine replacement therapy may be documented on a prescription form, and the form may be assigned a number for recordkeeping purposes.

(2) Not later than seventy-two hours after a screening is conducted under this rule and the patient has been identified as a candidate for smoking cessation therapy, the pharmacist shall provide notice to the individual's primary care provider, if known, or to the individual if the primary care provider is unknown. The notice shall include results of the screening, and if applicable, the dispensing record and follow-up care plan. Notification shall be conducted using one of the following methods that is capable of confirming delivery of the required notification:

(a) Electronic mail;

(b) Interoperable electronic medical records system;

(d) Electronic prescribing system;

(e) Electronic pharmacy record system;

(f) Documented verbal communication; or

(g) Any other method of notification that might reasonably be expected to allow for the confirmed transmission of the required notification.

(3) A copy of the documentation identified in paragraph (E)(1) of this rule shall also be provided to the individual or the individual's primary care provider on request.

(F) This rule does not affect the authority of a pharmacist to do any of the following:

(1) Fill or refill prescriptions for nicotine replacement therapy;

(2) Sell nicotine replacement therapy that does not require a prescription.

(G) A provider who is not accredited by the accreditation council for pharmacy education may petition the board for approval of a course in accordance with division (C) of section 4729.284 of the Revised Code. The board shall develop and post a petition application on its website providing the criteria for approval.

(H) No pharmacist shall do either of the following:

(1) Dispense nicotine replacement therapy in accordance with a protocol unless the requirements of paragraph (C) of this rule have been met;

(2) Delegate to any person the pharmacist's authority to engage in or supervise the dispensing of nicotine replacement therapy.

(I) A terminal distributor of dangerous drugs shall ensure that all pharmacists that dispense nicotine replacement therapy pursuant to this rule have completed the requirements set forth in paragraph (C) of this rule.

(J) A terminal distributor of dangerous drugs dispensing nicotine replacement therapy in accordance with this rule shall also comply with the applicable record keeping provisions of Chapter 4729:5-5, 4729:5-8, or 4729:5-9 of the Administrative Code.

Last updated June 11, 2026 at 11:17 AM

History

Effective: May 6, 2022
Promulgated Under: 119.03

Chapter 4729:1-4 Discipline and Duty to Report

Ohio Adm.Code 4729:1-4-01 Disciplinary actions.